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Abstract
Background: Several reports indicate the high-affinity receptor of NT (neurotensin), NTR1 (neurotensin receptor 1),
in numerous detrimental functions linked to neoplastic progression of several cancer types. Recently, it has also
been shown that NTR1 gene is a target of the Wnt/APC oncogenic pathways connected with the β-catenin/Tcf
transcriptional complex and NT can stimulate cancer proliferation in an EGFR-dependent mechanism. In this study,
we explored NTR1, β-catenin and EGFR expression in gastric cancer. The possible associations of NTR1 expression
with clinicopathological factors, prognosis, β-catenin and EGFR were analyzed.
Methods: NTR1, β-catenin and EGFR expression in gastric cancer tissues and the adjacent normal tissues of 210 cases
was detected by Immunohistochemistry. The possible associations of NTR1 expression with clinicopathological data,
prognosis, β-catenin and EGFR were analyzed.
Results: 1. NTR1 expression in tumor tissues was significantly higher than that in adjacent normal tissues (P <0 .01). 2.
Its expression was positively correlated with pathological grade, T stage, N stage and TNM stage and was not
correlated with sex, age, tumor size and Lauren’s classification. 3. A co-expression of NTR1 and nuclear β-catenin was in
53 (25.2 %) of cases and NTR1 expression was positively correlated with β-catenin nuclear translocation. NTR1
expression was not correlated with EGFR expression, but at a critical value (P = 0.05). 4. By log-rank test, higher
expression of NTR1, higher pathological grade, diffusion Lauren’s classification and advanced TNM stage showed worse
prognosis (P <0 .05). Age, sex, tumor size, β-catenin and EGFR had no prognostic significance. Multivariate Cox analysis
showed that NTR1 expression and TNM clinical stage (P <0 .05) were the independent prognostic factors for patients
with GC.
Conclusion: By immunohistochemistry, we found that a high expression of NTR1 in GC specimens, which showed a
bad prognosis, besides, NTR1 expression was related to invasion and migration of GC. These findings provide new and
important information on the progression of GC. This study indicated that NTR1 may play an important role in tumor
progression of GC and have its potential to be a predictive biomarker or a therapeutic molecular target in GC. The
interaction between NTR1 and β-catenin may participate in the development of GC. However, the relationship
between NTR1 and EGFR needs to be further investigated.
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Background
Gastric cancer is a frequent cause of cancer-related
death in the world [1]. In China, gastric cancer ranks the
third most common cancer [2]. Although the establish-
ment of screening, early diagnosis and curative operation
has increased survivals significantly, recurrence and
metastasis remains a great challenge for patients with
gastric cancer. Gastric cancer development is often asso-
ciated with a number of molecular abnormalities, includ-
ing the inactivation of various tumor suppressor genes
and/or activation of various oncogenes [3, 4], but the
mechanism of the development, invasion and metastasis
of gastric cancer is still not clear. Investigations into the
molecular alterations in gastric cancer may provide
novel insights into the mechanisms responsible for
stomach carcinogenesis and lead to the development of
biomarkers for the early detection of gastric cancer and
the prediction of its prognosis.
Neurotensin (NT) and its cognate receptor (neuroten-
sin receptor 1, NTR1) are neuropeptide-receptor com-
plexes frequently deregulated during the neoplastic
process. NT is a 13-amino-acid peptide previously rec-
ognized for its distribution along the gastrointestinal
tract [5]. The effects of NT are mediated by binding to
three neurotensin receptors NTR-1, -2, and -3. The
NTR1 and NTR2 are G-protein coupled receptors, while
the NTR3 belongs in the sortilin receptor superfamily.
The peripheral functions of NT are mainly mediated
through its interaction with NTR1, a high affinity recep-
tor coupled to a Gq/G11 protein [6]. Several reports im-
plicate NTR1 in numerous detrimental functions linked
to neoplastic progression of several cancer types, includ-
ing pancreatic, prostate, colon, lung and head and neck
cancers [7, 8]. In vivo and in vitro NT effects are abol-
ished by the specific antagonist of NTR1, SR48692,
which implies that NTR1 is a major mediator of these
transforming actions [9].
NTR1 activation leads to cell proliferation, survival,
mobility, and invasiveness in specific cancer cell types
via signal transduction through PKC, extracellular
signal-regulated kinase 1 and 2, RhoGTPases, NF-κB, or
focal adhesion kinase activation [10–12]. Some studies
suggest that NT can stimulate many cancer proliferation
in an EGFR-dependent mechanism, including foregut
neuroendocrine tumor, prostate, colon and non-small
cell lung cancers [13]. Recently, it has been shown that
NTR1 gene is a target of the Wnt/APC oncogenic path-
ways connected with the β-catenin/Tcf transcriptional
complex, known to activate genes involved in cell prolif-
eration and transformation [14].
The expression of NTR1 and its relationship with
EGFR and β-catenin in gastric cancer have not been
reported. In this study, we explored NTR1, β-catenin
and EGFR expression in gastric cancer. The possible
associations of NTR1 expression with clinicopathological
factors, prognosis, β-catenin and EGFR were analyzed.
Methods
Patients
A total of 210 patients with histologically confirmed gas-
tric adenocarcinoma invading the submucosal layer or
deeper were retrospectively included in this study. All
patients received the curative gastrectomy with lymph
node dissection in our department of Wuxi People’s
Hospital Affiliated to Nanjing Medical University (Wuxi,
China) between January 2011 and December 2011. No
patients underwent chemotherapy or radiotherapy prior to
surgery. A matched distant non-cancerous sample (5 cm
away from the lesion) was also obtained from each patient
and used as a control. The clinicopathological characteris-
tics of the patients included age, gender, tumor size, patho-
logical grade, Lauren’s classification, TNM stage and lymph
node metastasis status.
The median age of the patients was 64 years, ranging
from 34 to 90 years. There were 160 males and 50
females (3.2:1). According to tumor differentiation, there
were 93 (44.3 %) well and moderate differentiated tu-
mors and 117 (55.7 %) poor and undifferentiated tu-
mors. According to TNM stage, 51 (24.3 %) patients
were at T1-2 stage while the left 159 (75.7 %) patients
were at T3-4 stage. 157 (74.8 %) patients were positive
and 53 (25.2 %) were negative for lymph node metasta-
sis. There were 63 (30.0 %) stage I-II and 147 (70.0 %)
stage III-IV patients. Follow-up information, including
patients’ outcome and the time interval between the date
of surgical resection and the date of the cancer-related
death, was collected. Those cases lost to follow-up and
died from causes other than gastric cancer were
regarded as censored data for the analysis of survival.
The study was approved by our local ethics commit-
tees. Specimens were obtained with informed consent
in accordance with the ethical standard of the Helsinki
Declaration of 1975, as revised in 2000.
Immunohistochemistry
Paraffin slices were treated according to the EnVision
immunohistochemical kit, and results were analyzed
using a double-blind method. Two pathologists evalu-
ated scores independently. PBS, instead of the pri-
mary antibody, was used as negative control. For
NTR1 (polyclonal antibody, abcam, using a concen-
tration of 5 μg/ml) staining, the degree of expression
was categorized as negative (positive staining of <10 %
of tumor cells), positive (positive staining of ≥10 % and
<50 % of tumor cells), or strongly positive (positive
staining involving ≥50 % of tumor cells) [15].
According to Aust et al. [16], a semi-quantitative
evaluation of β-catenin (monoclonal antibody, MAB-
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259, Fuzhou Maixin Biotech. Co., Ltd, Pre-diluted) nu-
clear translocation was performed by estimating the per-
centage of positive nuclei as follows: 0; 1: 0 to 5 %; 2:5 to
25 %; 3: up to 25 %, and a cut-off of >5 % of positive β-
catenin nuclei (score 2 or more) was considered signifi-
cant for nuclear translocation of the protein.
EGFR (monoclonal antibody, RMA-0554, Fuzhou
Maixin Biotech. Co., Ltd, Pre-diluted) reactivity was
scored as 0 if there was no membranous reactivity
within the tumor, or as 1+, 2+, or 3+ depending on
the intensity above the background level [17]. The
score of 1+ to 3+ was defined as positive and the
score of 0 was defined as negative [18].
Statistical analysis
All data were analyzed using SPSS 18.0. x2 tests (or
Fisher’s exact test) were used for samples classified
as percentages; The spearman analysis was used to
determine the correlation between two variables.
Both the Kaplan–Meier method and log-rank test
were used for single variant analysis, and a Cox
model was used to analyze relationships between
survival rates and multiple variables. P < 0.05 was
considered statistically significant.
Results
NTR1 expression in tumor tissues was significantly higher
than that in adjacent normal tissues and was positively
correlated with pathological grade, T stage, N stage and
TNM stage
According to the criteria established for immunostain-
ing, 71.0 % (149/210) of tumors were positive for NTR1
staining. Only 28 (13.3 %) cases were positive in adja-
cent normal gastric mucosa. By way of the x2-test,
NTR1 expression of tumor tissues was significantly
higher (P <0.01) (Fig. 1).
By way of Spearman analysis, NTR1 expression was
positively correlated with pathological grade (Fig. 2),
T stage, N stage and TNM stage and was not corre-
lated with sex, age, tumor size and Lauren’s classifica-
tion (Table 1).
NTR1 expression was positively correlated with β-catenin
nuclear translocation and was not correlated with EGFR
expression
Using immunohistochemical analysis, we observed a co-
expression of NTS1 and nuclear β-catenin in 25.2 %(53)
of cases and NTR1 expression was positively correlated
with β-catenin nuclear translocation (P <0.05) (Figs. 3, 4
Fig. 1 Expression of NTR1 in gastric cancer tissues (200×). Strongly positive NTR1 expression in intestinal-(a) and diffuse–type (b) of gastric cancer
tissues; negative NTR1 expression in the adjacent normal gastric mucosa (c)
Fig. 2 Expression of NTR1 in intestinal-type of gastric cancer tissues (200×). Positive NTR1 expression in well differentiated intestinal-type of gastric
cancer tissues (a); Strongly positive NTR1 expression in poor differentiated intestinal-type of gastric cancer tissues (b)
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and 5) and was not correlated with EGFR expression
(Fig. 6), however at a critical value (P = 0.05) (Table 2).
Higher expression of NTR1, higher pathological grade,
diffusion Lauren’s classification and TNM stage showed
worse prognosis and high NTR1 expression and TNM
clinical stage were the independent prognostic factors for
patients with GC
We conducted NTR1 survival analysis on 210 cases of
gastric cancer with follow-up data. The 1-year and 3-
year survival rates of 210 cases were 78.9 % and 68.0 %.
Patients with higher NTR1 expression showed a more
unfavorable prognosis than those with no expression
(P <0 .01) (Fig. 7). By log-rank test, higher expression of
NTR1 (P =0.000), higher pathological grade (P =0.014),
diffusion Lauren’s classification (P =0.004), advanced
T stage (P =0.026), TNM stage (P =0.000), and N
stage (P =0.000) showed worse prognosis, and age,
sex and tumor size had no prognostic significance.
Multivariate Cox analysis showed that the following
factors were the independent prognostic factors for
patients with GC: NTR1 expression and TNM clinical
stage (P <0 .05) (Table 3).
Discussion
NT has been shown to exert numerous oncogenic ef-
fects involved in tumor growth and metastatic spread.
These effects are mostly mediated by NTR1, making
NTR1 an actor in cancer-progression [7, 19]. Recently, it
was found that the expression of NTR1 was significantly
correlated to an increase in the number of tumors when
sporadic cancer was generated in mouse models by in-
flammation [20]. Vias et al. [21] found that long-term
anti-androgen treatment of LNCaP cells produced a
sub-line exhibiting up-regulated expression of NT and
NTRs, which increased the proliferation rate, accelerated
cell cycle progression, and increased invasiveness. NTR1
expression was also found at very high levels in the hu-
man androgen-independent PC3 cell line. In pancreas,
NT binding sites were found specifically in pancre-
atic cancer but not in normal pancreas and chronic
Table 1 Clinicopathologic features and the expression of NTR1






<60 15 27 23
≥60 46 53 46
Sex 0.315
Male 44 61 55
Female 17 19 14
Tumor size (cm) 0.291
<5 34 21 31
≥5 27 59 38
Pathological grade 0.027
Well and moderate 34 34 25
Poor and undifferentiated 27 46 44
Lauren’s classification 0.125
Intestinal 32 39 27
Diffusion 18 20 24
Mixed 11 21 18
T stage 0.001
T1-2 26 14 11
T3-4 35 66 58
N stage 0.000
Positive 33 66 58
Negative 28 14 11
TNM stage 0.011
I- II 28 18 17
III-IV 33 62 52
*Spearman analysis
Fig. 3 β-catenin expression in gastric cancer and adjacent normal gastric mucosa (200×). Nuclear ß-catenin expression in gastric cancer (a) and
nomal ß-catenin membrane staining in the adjacent normal gastric mucosa (b)
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pancreatitis [22]. Moderate to strong expression of
NTR1 in colonic adenomas and adenocarcinomas
suggest that increased NTR1 expression may be an
early event during colonic tumorigenesis in colonic
adenocarcinomas [23]. Using immunohistochemical
analysis, we found NTR1 protein was up-regulated
obviously in 71 % of the patients than that in adja-
cent normal tissues and was correlated with clinico-
pathological factors and prognosis, therefore
speculating NTR1 gene over-expression may be in-
volved in the pathogenesis of GC.
Besides the contribution of NTR1 expression in tumor
progression and aggressive behavior [23], it was also
identified as a prognosis marker in colon, breast, lung,
and head and neck carcinomas and malignant pleural
mesothelioma [19, 24]. In pancreatic cancer, the NTR1
mRNA levels were higher in advanced tumor stage
(stages III and IV) than early tumor stage (stages I
and II) [25]. In breast invasive carcinomas, the high
expression of NTR1 was associated with the SBR
grade, the size of the tumor, and the number of
metastatic lymph nodes [26]. In colonic adenocarcin-
omas, adenocarcinomas that infiltrated into and beyond
the muscularis propria showed a higher intensity of
NTR1 expression compared with tumors that were lo-
calized to the mucosa or submucosa. In some cases, in-
filtrating margins and foci of lymphovascular invasion
showed a higher intensity of expression than the main
mass of the tumor [23]. In head and neck squamous
cell carcinomas, NT and NTR1 mRNA high levels were
significantly correlated with higher rates of distant me-
tastasis as well as with the survival rate [8]. Experimen-
tal tumor xenografts generated by NT- and NTR1-
silenced human lung cancer cells revealed that NT en-
hanced primary tumor growth and production of
massive nodal metastasis via autocrine and paracrine
regulation loops [15]. Investigating the biological role of
NTR1 expression in GC by IHC, we found that NTR1
expression was positively correlated with histologic
grade, TNM stage and lymph node metastasis in GC.
Univariate analysis showed that the following factors
were significantly related to postoperative survival in
GC: NTR1 expression and TNM clinical stage. Our re-
sults suggest that NTR1 is a potential marker and/or a
pejorative mediator of gastric cancer progression associ-
ated with poor prognosis. Lymph node metastasis is
usually a reliable prognostic indicator, but skip metasta-
ses and micrometastases easily lead to missed diagnosis
in routine pathology work. Tumor stage is a prognostic
factor, however it is relatively hysteretic for prognosis.
Therefore, high expression of NTR1 could lead to clin-
ical attention even without lymph node metastasis. Cur-
rently, further studies are needed on molecular
mechanism of NTR1 promoting invasion and metastasis
Fig. 4 Expression of NTR1 and β-catenin in intestinal-type of gastric cancer tissues (200×). HE staining image (a), IHC staining of NTR1 (b) and
nuclear ß-catenin expression (c) in the same region of the same intestinal-type cases. ×200
Fig. 5 Expression of NTR1 and β-catenin in diffuse-type of gastric cancer tissues (200×). IHC staining of NTR1 and β-catenin in the same case of
the diffuse-type cases. ×200
Zhou et al. Diagnostic Pathology  (2015) 10:128 Page 5 of 9
and investigations of whether NTR1 could be used as a
target for novel therapeutic approaches in GC.
EGFR transactivation by NT/NTR1 complex has
been observed in several cell lines. In PC3 prostate
cancer cells, NT activates proliferation through EGFR
transactivation in a PKC (protein kinase C, PKC)-
dependent pathway [27, 28]. In the colonic HCT116
cells, NT/NTR1 induces a PKC-dependent ERK phos-
phorylation and an EGFR metalloproteinase-mediated
transactivation, however, in colonic HT-29 cells, the
EGFR tyrosine kinase inhibitor, gefitinib, blocks NTS-
stimulated phosphorylation of both ERK and Akt, in-
dicating the transactivation of EGFR independently of
PKC. The activation of Akt is only partly inhibited by
gefitinib, suggesting an multiple mechanism to EGFR
transactivation in a partially redundant manner [29].
The mechanism of NT-induced EGFR transactivation
is still not clearly elucidated. The release of EGFR
ligands-like (TGF-α, Hb-EGF, or amphiregulin), as
pro-ligand, by NT has been proposed. These ligands
are released by proteolytic cleavage involving enzymes
of the metalloproteinase family [30–32]. Once released,
these ligands bind to EGFR and activate the down-
stream signaling cascades of EGFR activation [27].
These findings suggest a cooperative relationship be-
tween the neurotensinergic system and EGFR pathway.
However, Massa F et al. observed that although both
NT and EGF enhance colonic epithelial cells growth,
the intracellular pathways involved in these effects are
quite independent and NT is unable to transactivate
EGFR in two cell lines, HT29 and HCT116 [33], in con-
trast to results obtained in other colonic and prostatic
cancer cell lines [27, 34]. These distinct pathways could
be the consequence of the co-expression of NTR1 and
NTR3 that are shown to be involved in complex for the
signaling of NT [6]. Olszewski-Hamilton U. et al. [35]
revealed dependence of relative expression of NTR1
and EGFR on cell density and extracellular pH in hu-
man pancreatic cancer cell lines. They suggested that
downregulation of EGFR at higher cell densities con-
comitant with upregulation of NTR1 seems to indicate
mutual exclusive roles for these receptors. EGFR may
be important in the initial growth of pancreatic tumor
cells and replaced by increased expression of other
growth factor receptors, like NTR1, during metastatic
dissemination. Taken together, these observations indi-
cate that the cellular pathways leading to cell prolifer-
ation by NT and EGF are more complex in some
cancer cell lines and that the ways to develop tools to
decrease tumor growth remain more complicated than ex-
pected from previous studies. Using immunohistochemi-
cal analysis, we found that NTR1 expression was not
correlated with EGFR expression, however at a critical
value (P = 0.05). We think that, in addition to the limited
number of cases, this phenomenon may be due to the het-
erogeneity in gastric cancer. NTR1 expression may be cor-
related with EGFR expression in certain types, while not
in some other types, thus needing to be further confirmed
by cell gene technology.
Some other mechanisms may exist, recently NTR1
gene expression induced by the accumulation of β-
catenin in human colonic adenomas has been found.
In support of this hypothesis, analysis of the regula-
tory sequences in the NTR1 gene revealed the pres-
ence of a consensus T cell factor (Tcf ) binding site
potentially linking the activation of the NTR1 and
APC (adenomatous polyposis coli)/b-catenin pathway.
Fig. 6 EGFR expression in gastric cancer and adjacent normal gastric mucosa. Positive EGFR expression (score 3+) in gastric cancer (a) and
negative EGFR expression in the adjacent normal gastric mucosa (b)
Table 2 Correlation between NTR1 and β-catenin nuclear
translocation and EGFR expression in gastric cancer
Item NTR1 Expression intensity p-value*
Negative Positive Strongly
positive
Nuclear ß-catenin expression 0.034
Negative 42 60 36
Positive 19 20 33
EGFR expression 0.050
Negative (score 0) 29 24 21
Positive (score 1-3+) 32 56 48
*Spearman analysis
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It has been demonstrated that inhibitors of GSK-3β
(protein kinase involved in the phosphorylation of β-
catenin and its degradation) which cause the signifi-
cant accumulation of β-catenin, upregulate the level
of NTR1 transcription [36]. During inflammatory
bowel disease-related oncogenesis, two pathways of
NTR1 overexpression existed: one triggered by NT
overexpression, and a second associated with β-
catenin nuclear accumulation, both being not mutu-
ally exclusive [37]. Similar results have been obtained
in other cancers such as lung, prostate, and breast
cancers [38, 39]. In our study, we found that NTR1
expression was associated with nuclear ß-catenin ex-
pression, suggesting that the interaction between
NTR1 and β-catenin may participate in the develop-
ment of GC. What needs to be further confirmed is
whether β-catenin upregulate the level of NTR1 ex-
pression or upregulated NTR1 expression potentiate
β-catenin nuclear translocation and thus activate β-
catenin mediated signaling pathway.
Fig. 7 Overall survival curves of patients with gastric cancer according to the immunostaining results of NTR1. Higher expression of NTR1
(P =0.000) showed worse prognosis
Table 3 Multiple factor Cox model regression variable form of gastric cancer
Item B SE Wald df Sig.a Exp (B) 95.0 % CI for Exp (B)
Lower Upper
NTR1 Expressin Intensity 0.444 0.186 5.686 1 0.017 1.559 1.082 2.245
N stage 3.097 1.122 7.624 1 0.006 22.139 2.457 199.522
aCox model analysis
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Conclusion
By immunohistochemistry, we found the association
between NTR1 and GC specimens, in which patients
with high NTR1 expression have a bad prognosis.
The relationship between NTR1 and invasion and mi-
gration of GC was revealed. These findings provide
new and important information on the progression of
GC. This study indicated that NTR1 may play an im-
portant role in tumor progression of GC and have its
potential as a predictive biomarker and a therapeutic
molecular target in GC. The interaction between NTR1
and β-catenin may participate in the development of
GC, while the relationship between NTR1 and EGFR
needing to be further investigated.
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